These risks are of particular concern in pediatric patients because of the life-long nature of these disorders' said Thomas Laughren, director of the FDA's psychiatric product division, in a memo.

“儿科患者使用这些药物的风险受到特别关注，因为这些精神疾病是终身的”，美国食品和药物管理局的精神疾病药物部门主任，托马斯拉夫雷在一份备忘录里说。

youdao

In an interview, FDA psychiatry drugs unit director Thomas Laughren says he supports more studies in patients at high-risk of suicide, and has given speeches to that effect.

FORBES: The Sick Patients Glaxo, Pfizer, and Lilly Refuse To Help